Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.
Schmidt P, Gong J, Narayan K, Gupta D, Engler F, Li Y, Copans A, Campanaro E. Schmidt P, et al. Among authors: engler f. Infect Dis Ther. 2023 May;12(5):1365-1377. doi: 10.1007/s40121-023-00794-1. Epub 2023 Apr 25. Infect Dis Ther. 2023. PMID: 37185797 Free PMC article.
Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
Li Z, Follman K, Freshwater E, Engler F, Yel L. Li Z, et al. Among authors: engler f. Int Immunopharmacol. 2023 Jan;114:109555. doi: 10.1016/j.intimp.2022.109555. Epub 2022 Dec 15. Int Immunopharmacol. 2023. PMID: 36527876 No abstract available.
48 results